Gilde Healthcare leads €12.2m AM-Pharma round

AM-Pharma's existing backers AbbVie, BB Biotech Ventures, Idinvest Partners, Inventages Venture Capital, Kurma Life Sciences Partners (KLS) (via the Kurma Biofund) and Ysios Capital Partners took part in the round.

The fresh capital will be used by AM-Pharma to complete a 290-patient phase-II study for the development of its recombinant human Alkaline Phosphatase (recAP) treatment for acute kidney injury.

The funding will also allow the biotech to continue developing the oral formulation of recAP, designed to treat ulcerative colitis, and prepare the therapy for phase-II trial.

Previous funding
The deal marks the fifth funding round for AM-Pharma, according to unquote" data. The company's most recent round took place in September 2011, when it raised €29.2m from Ysios, KLS, BB Biotech Ventures, Forbion Capital Partners, Idinvest and Inventages. Ysios and KLS led the round, with the former contributing €4.5m in capital.

Prior to that, in May 2008, Forbion and Inventages provided the company with €7m in funding. At the time, AM-Pharma was making preparations for a potential IPO.

In August 2007, the two firms contributed €2.5m to the biotech. Previously, in October 2005, Inventages and ABN Amro Life Sciences Capital provided AM-Pharma with €6m and €3m respectively.

Company
Founded in 2001 and headquartered in Bunnik, AM-Pharma focuses on the development of its recAP therapeutics for the treatment of acute kidney injury and inflammatory bowel diseases.

People
Erik van den Berg is the CEO of AM-Pharma. Gilde Healthcare managing director Edwin de Graaf will join the company's supervisory board. The board already includes Ysios partner Joël Jean-Mairet, KLS managing partner Rémi Droller, BB Biotech's Klaus Breiner, Forbion partner Geert-Jan Mulder and AbbVie venture investments head David Donabedian.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Benelux
• Early-stage
• Healthcare
• Gilde Investment Management
• IDInvest Partners (AGF Private Equity)
• Ysios Capital
• Netherlands